Immuven Opens Lab in EnterpriseWorks

ImmuVen, Inc. is a biotech start-up that is developing high-affinity T cell receptors, a novel class of immune-targeting drugs and diagnostic agents. The company is founded by a leading expert in the field, UI Chemistry professor Dr. David Kranz. The company is licensing technology from the University of Illinois and will have broad coverage of its IP position in the area of T cell receptor proteins for use in a range of diseases (cancer, autoimmune diseases) through key strategic partnerships. The new laboratory facility for ImmuVen opened this week in EnterpriseWorks.